132eP Prognostic uncertainty in refractory mCRC: Evaluating outcomes with TAS-102 plus bevacizumab beyond traditional classification in a real-world settingPaulo Frazão, Ana María Martins, Thalita Silva Martins et al.|Annals of Oncology|2025Cited by 0